Intrinsiqq
Precigen Inc. logo

Precigen Inc. Financials

PGEN

⊜ Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 16 available years
Income Statement
TTM
~1.3:1 split
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue$157$10$4$6$27$14
General & Administrative$83$70$41$40––
Research & Development$27$41$53$49––
Provision for Doubtful Accounts––$0$0$1$1
Total Operating Expenses$123$120$139$106––
Operating Income$34-$111-$135-$100––
Non-Operating
Net Interest Expense-$12-$4-$0-$0––
Other Non-Operating Income (Expense)$3-$136$7$4––
EBT (Earnings Before Tax)$25-$251-$128-$96-$80-$111
Income Tax Expense$0$0-$2-$0-$0-$0
Earnings from Continuing Ops––––-$80-$97
Minority Interest–––––$0
Net Income
Net Income$24-$251-$126-$96$28-$92
Per Share Data
Revenue Per Share$0.37$0.03$0.01$0.03$0.13$0.07
EPS (Basic)$0.10-$1.37-$0.47-$0.39$0.14-$0.47
EPS (Diluted)$0.07-$1.37-$0.47-$0.39$0.14-$0.47
Weighted Avg Shares (Basic)358.2M313.0M267.7M244.5M200.4M197.8M
Weighted Avg Shares (Diluted)421.2M313.0M267.7M244.5M200.4M197.8M
Shares Outstanding421.2M313.0M267.7M244.5M200.4M197.8M

Precigen (PGEN) financials: revenue, profit and margins

Precigen (PGEN) generated about n/a in revenue and -$158 million in net income (a -2,588.2% net margin) over the trailing twelve months, growing at roughly -21.3% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Precigen profitable?+

Precigen reported about -$158 million in net loss over the trailing twelve months, a net margin of roughly -2,588.2%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Precigen's profit margins?+

Precigen runs an operating margin of about -1,141.1%, a net margin of about -2,588.2%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is Precigen growing?+

Precigen's revenue has compounded at roughly -21.3% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside PGEN's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 5 Aug 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with PGEN

CompareIntrinsic value
ZBIOZenas BioPharma, Inc.
$28.46+0.28%10
HOOKHookipa Pharma Inc.
No recent price20
ISCOInternational Stem Cell Corporation
$0.14+0.00%29
BIOABioAge Labs, Inc.
$5.95-0.17%10
CBIOCrescent Biopharma, Inc.
$13.42+2.76%50
ALMSAlumis Inc.
$6.55+0.77%10
ACRSAclaris Therapeutics, Inc.
$3.68-1.60%10
ROIVRoivant Sciences Ltd
$38.23+6.08%16

Held by ETFs

PGEN is in 35 US ETFs. The largest of them, with PGEN's weight in each:

Spot a number that looks wrong? Check it in PGEN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PGEN

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.